NNC0363-1063 / Novo Nordisk - LARVOL DELTA

A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=154 | Recruiting | Sponsor: Novo Nordisk A/S | Trial completion date: Jul 2025 ➔ May 2026 | Trial primary completion date: Jul 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes (clinicaltrials.gov) - P1 | N=154 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus